Cost Savings of Aggressive Dose De-Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma Versus Standard of Care; Cost Analysis of a Prospective Phase II Study
Mark R. Waddle(Mayo Clinic), Robert C. Miller(Mayo Clinic), Eric J. Moore(Mayo Clinic), Darlene E. Graner(Mayo Clinic in Arizona), Katharine A. Price(WinnMed), Samir H. Patel(WinnMed), Jeffrey R. Janus(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Jan L. Kasperbauer(Mayo Clinic), Ashish V. Chintakuntlawar(Mayo Clinic Hospital), Jackson May(Mayo Clinic in Arizona), Daniel L. Price(Mayo Clinic in Arizona), Robert L. Foote(Mayo Clinic), Yolanda I. Garces(Mayo Clinic), Javier García(Hospital General Yagüe), M.L. Hinni(WinnMed), Sue L. Visscher(Mayo Clinic)
International Journal of Radiation Oncology*Biology*Physics
October 20, 2018
Cited by 0
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632